Drug intelligence / Profile preview

alpha-viniferin

Development stage
Preclinical
Modality
Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

**alpha-viniferin** is a naturally occurring stilbenoid trimer (specifically, a resveratrol trimer) belonging to the class of 2-arylbenzofuran flavonoids, with the molecular formula C42H30O9 and a molar mass of 678.68 g/mol[2][3][5][6][7]. It is principally isolated from several plant species, notably Caragana chamlagu, Caragana sinica, Caragana korshinskii, and is found in Vitis vinifera (grapes)[2][3][7]. Biologically, it functions as a plant metabolite, prostaglandin H2 synthase inhibitor, anti-inflammatory agent, acetylcholinesterase inhibitor, anti-oxidant, anti-arthritis agent, and anti-tumor agent[2][4][9][10][12]. Mechanistically, alpha-viniferin exhibits: - **Reversible, non-competitive inhibition of acetylcholinesterase (AChE)**, enhancing cholinergic neurotransmission and offering therapeutic potential for neurodegenerative diseases such as Alzheimer's disease[1][2][4]. - **Dose-dependent inhibition of cyclooxygenase (COX) activity**, implicating anti-inflammatory and anti-tumor effects[4][11]. - **Anti-angiogenic activity** by inhibiting endothelial cell proliferation and migration (via VEGFR-2/p70 S6 kinase pathway), potentially relevant in atherosclerosis and cancer[1]. Other reported activities include inhibition of matrix metalloproteinase-2, suppression of STAT-1-inducible inflammatory gene expression (in IFN-γ-stimulated macrophages via ERK/STAT-1 pathway), and modulation of retinoblastoma protein phosphorylation[1][4][11]. alpha-viniferin is investigated for **anti-tubercular activity**[10], neuroprotective effects, and potential biomarker of grape and wine consumption[3]. Bioavailability is low (~4.2%) after oral administration in animal models[1].

Other names
α-viniferinalpha-Viniferin(+)-alpha-viniferin
02

Targets

NOS1 (nNOS)STAT1 (Signal transducer and activator of transcription protein 1)AcetylcholinesteraseMpro (3C-like proteinase of SARS-CoV-2)VEGFR2 (Vascular endothelial growth factor receptor 2)MMP2 (Matrix metalloproteinase-2)

Beyond the preview

Go deeper on alpha-viniferin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-viniferin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call